{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:27:00Z","timestamp":1794320820464,"version":"4.9.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucopolysaccharidoses (MPS) are rare, inherited lysosomal storage disorders characterized by progressive multiorgan involvement. Previous studies on incidence and prevalence of MPS mainly focused on countries other than the United States (US), showing considerable variation by country. This study aimed to identify MPS incidence and prevalence in the US at a national and state level to guide clinicians and policy makers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study examined all diagnosed cases of MPS from 1995 to 2015 in the US using the National MPS Society database records. Data included year of birth, patient geographic location, and MPS variant type. US population information was obtained from the National Center for Health Statistics. The incidence and prevalence rates were calculated for each disease. Incidence rates were calculated for each state.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We obtained information from 789 MPS patients during a 20-year period. Incidence of MPS in the US was found to be 0.98 per 100,000 live births. Prevalence was found to be 2.67 per 1\u00a0million. MPS I, II, and III had the highest incidence rate at birth (0.26\/100,000) and prevalence rates of 0.70\u20130.71 per million. Birth incidences of MPS IV, VI, and VII were 0.14, 0.04 and 0.027 per 100,000 live births.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the most comprehensive review of MPS incidence and prevalence rates in the US. Due to the large US population and state fragmentation, US incidence and prevalence were found to be lower than other countries. Nonetheless, state-level studies in the US supported these figures. Efforts should be focused in the establishment of a national rare disease registry with mandated reporting from every state as well as newborn screening of MPS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-01880-8","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T05:04:02Z","timestamp":1625547842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities"],"prefix":"10.1186","volume":"16","author":[{"given":"Yana","family":"Puckett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Mallorga-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-5789","authenticated-orcid":false,"given":"Adriana M.","family":"Monta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,29]]},"reference":[{"key":"1880_CR1","unstructured":"Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet A, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. 8th ed. McGraw-Hill; 2001. p.\u00a03421\u201352."},{"issue":"3","key":"1880_CR2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","volume":"167","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267\u201377.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"1880_CR3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/humu.1189","volume":"18","author":"G Yogalingam","year":"2001","unstructured":"Yogalingam G, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: diagnostic, clinical, and biological implications. Hum Mutat. 2001;18(4):264\u201381.","journal-title":"Hum Mutat"},{"issue":"4","key":"1880_CR4","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1086\/508068","volume":"79","author":"X Fan","year":"2006","unstructured":"Fan X, Zhang H, Zhang S, Bagshaw RD, Tropak MB, Callahan JW, et al. Identification of the gene encoding the enzyme deficient in mucopolysaccharidosis IIIC (Sanfilippo disease type C). Am J Hum Genet. 2006;79(4):738\u201344.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1880_CR5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.22092","volume":"68","author":"MJ Valstar","year":"2010","unstructured":"Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJ, Wevers RA, et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype\u2013phenotype correlations. Ann Neurol. 2010;68(6):876\u201387.","journal-title":"Ann Neurol"},{"issue":"11","key":"1880_CR6","doi-asserted-by":"crossref","first-page":"6822","DOI":"10.1073\/pnas.77.11.6822","volume":"77","author":"H Kresse","year":"1980","unstructured":"Kresse H, Paschke E, von Figura K, Gilberg W, Fuchs W. Sanfilippo disease type D: deficiency of N-acetylglucosamine-6-sulfate sulfatase required for heparan sulfate degradation. Proc Natl Acad Sci USA. 1980;77(11):6822\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1880_CR7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","volume":"30","author":"AM Monta\u00f1o","year":"2007","unstructured":"Monta\u00f1o AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30(2):165\u201374.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1880_CR8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ajmg.1320010206","volume":"1","author":"JW Spranger","year":"1977","unstructured":"Spranger JW. Beta galactosidase and the Morquio syndrome. Am J Med Genet. 1977;1(2):207\u20139.","journal-title":"Am J Med Genet"},{"issue":"6","key":"1880_CR9","first-page":"1127","volume":"58","author":"T Litjens","year":"1996","unstructured":"Litjens T, Brooks DA, Peters C, Gibson GJ, Hopwood JJ. Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet. 1996;58(6):1127\u201334.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1880_CR10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","volume":"53","author":"AM Monta\u00f1o","year":"2016","unstructured":"Monta\u00f1o AM, Lock-Hock N, Steiner RD, Graham BH, Szlago M, Greenstein R, et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. 2016;53(6):403\u201318.","journal-title":"J Med Genet"},{"key":"1880_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/uog.20371","volume":"55","author":"M Holtz","year":"2020","unstructured":"Holtz M, Monta\u00f1o AM, Sly WS. Association between mucopolysaccharidosis Type VII and hydrops fetalis. Ultrasound Obstet Gynecol. 2020;55:416\u20137. https:\/\/doi.org\/10.1002\/uog.20371.","journal-title":"Ultrasound Obstet Gynecol."},{"issue":"14","key":"1880_CR12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199610033351405","volume":"335","author":"MR Natowicz","year":"1996","unstructured":"Natowicz MR, Short MP, Wang Y, Dickersin GR, Gebhardt MC, Rosenthal DI, et al. Clinical and biochemical manifestations of hyaluronidase deficiency. N Engl J Med. 1996;335(14):1029\u201333.","journal-title":"N Engl J Med"},{"issue":"5","key":"1880_CR13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10545-011-9343-3","volume":"34","author":"L Imundo","year":"2011","unstructured":"Imundo L, LeDuc CA, Guha S, Brown M, Perino G, Gushulak L, et al. A complete deficiency of hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis. J Inherit Metab Dis. 2011;34(5):1013\u201322.","journal-title":"J Inherit Metab Dis"},{"key":"1880_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/8904_2015_467","volume":"25","author":"E Kiykim","year":"2016","unstructured":"Kiykim E, Barut K, Cansever MS, Zeybek CA, Zubarioglu T, Aydin A, et al. Screening mucopolysaccharidosis Type IX in patients with juvenile idiopathic arthritis. JIMD Rep. 2016;25:21\u20134.","journal-title":"JIMD Rep"},{"key":"1880_CR15","unstructured":"Publication N. Mucopolysaccharidoses Fact Sheet No. 03-5115, NINDS. https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Mucopolysaccharidoses-Fact-Sheet."},{"issue":"2","key":"1880_CR16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s13353-014-0262-5","volume":"56","author":"A Jurecka","year":"2015","unstructured":"Jurecka A, Lugowska A, Golda A, Czartoryska B, Tylki-Szymanska A. Prevalence rates of mucopolysaccharidoses in Poland. J Appl Genet. 2015;56(2):205\u201310.","journal-title":"J Appl Genet"},{"issue":"2","key":"1880_CR17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12687-015-0256-y","volume":"7","author":"SA Lynch","year":"2016","unstructured":"Lynch SA, Borg I. Wide disparity of clinical genetics services and EU rare disease research funding across Europe. J Community Genet. 2016;7(2):119\u201326.","journal-title":"J Community Genet"},{"issue":"8","key":"1880_CR18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jval.2014.08.2672","volume":"17","author":"JT Clarke","year":"2014","unstructured":"Clarke JT, Coyle D, Evans G, Martin J, Winquist E. Toward a functional definition of a \u201crare disease\u201d for regulatory authorities and funding agencies. Value Health. 2014;17(8):757\u201361.","journal-title":"Value Health"},{"issue":"11","key":"1880_CR19","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.bbadis.2013.04.016","volume":"1832","author":"F Stehr","year":"2013","unstructured":"Stehr F, Forkel M. Funding resources for rare disease research. Biochim Biophys Acta. 2013;1832(11):1910\u20132.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"1880_CR20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1651-2227.2005.tb02056.x","volume":"94","author":"I Autti-Ramo","year":"2005","unstructured":"Autti-Ramo I, Makela M, Sintonen H, Koskinen H, Laajalahti L, Halila R, et al. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland. Acta Paediatr. 2005;94(8):1126\u201336.","journal-title":"Acta Paediatr"},{"key":"1880_CR21","first-page":"Doc20","volume":"2","author":"P Schnell-Inderst","year":"2006","unstructured":"Schnell-Inderst P, Kunze S, Hessel F, Grill E, Siebert U, Nickisch A, et al. Screening of the hearing of newborns\u2014update. GMS Health Technol Assess. 2006;2:Doc20.","journal-title":"GMS Health Technol Assess"},{"issue":"2","key":"1880_CR22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4158\/EP13268.RA","volume":"20","author":"AG Moraitis","year":"2014","unstructured":"Moraitis AG, Martucci VL, Pacak K. Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma\/paraganglioma. Endocr Pract. 2014;20(2):176\u201387.","journal-title":"Endocr Pract"},{"key":"1880_CR23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pneurobio.2013.08.003","volume":"110","author":"JS Paulsen","year":"2013","unstructured":"Paulsen JS, Nance M, Kim JI, Carlozzi NE, Panegyres PK, Erwin C, et al. A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Progress in neurobiology. 2013;110:2\u201328.","journal-title":"Progress in neurobiology"},{"issue":"5","key":"1880_CR24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10545-011-9436-z","volume":"35","author":"R Giugliani","year":"2012","unstructured":"Giugliani R. Newborn screening for lysosomal diseases: current status and potential interface with population medical genetics in Latin America. J Inherit Metab Dis. 2012;35(5):871\u20137.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"1880_CR25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ddrr.132","volume":"17","author":"DJ Waggoner","year":"2011","unstructured":"Waggoner DJ, Tan CA. Expanding newborn screening for lysosomal disorders: opportunities and challenges. Dev Disabil Res Rev. 2011;17(1):9\u201314.","journal-title":"Dev Disabil Res Rev"},{"key":"1880_CR26","unstructured":"Advisory Committee on. Heritable Disorders in Newborns and Children. 2020."},{"key":"1880_CR27","unstructured":"Homepage R. 2016."},{"key":"1880_CR28","unstructured":"Laboratories AoPH. NewSTEPs. Newborn Screening Status for All Disorders. 2019 [Available from: https:\/\/www.newsteps.org\/resources\/newborn-screening-status-all-disorders."},{"issue":"1","key":"1880_CR29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","volume":"166","author":"PV Hopkins","year":"2015","unstructured":"Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166(1):172\u20137.","journal-title":"J Pediatr"},{"issue":"3","key":"1880_CR30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41436-018-0129-y","volume":"21","author":"MP Wasserstein","year":"2019","unstructured":"Wasserstein MP, Caggana M, Bailey SM, Desnick RJ, Edelmann L, Estrella L, et al. The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants. Genet Med. 2019;21(3):631\u201340.","journal-title":"Genet Med"},{"key":"1880_CR31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","volume":"190","author":"BK Burton","year":"2017","unstructured":"Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR, et al. Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience. J Pediatr. 2017;190:130\u20135.","journal-title":"J Pediatr"},{"key":"1880_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jpeds.2019.04.027","volume":"211","author":"JL Taylor","year":"2019","unstructured":"Taylor JL, Clinard K, Powell CM, Rehder C, Young SP, Bali D, et al. The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening. J Pediatr. 2019;211:193\u2013200.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2019.04.027.","journal-title":"J Pediatr."},{"issue":"8","key":"1880_CR33","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/gim.2017.194","volume":"20","author":"MM Minter Baerg","year":"2018","unstructured":"Minter Baerg MM, Stoway SD, Hart J, Mott L, Peck DS, Nett SL, et al. Precision newborn screening for lysosomal disorders. Genet Med. 2018;20(8):847\u201354.","journal-title":"Genet Med"},{"issue":"2","key":"1880_CR34","doi-asserted-by":"crossref","first-page":"s47","DOI":"10.1016\/j.ymgme.2017.12.107","volume":"123","author":"A Foley","year":"2018","unstructured":"Foley A, Cagle S, Hagar A, Hall P, Wilcox WR. Planning, implementation, and initial results of newborn screening for Pompe disease and MPS I in Georgia. Mol Genet Metab. 2018;123(2):s47.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1880_CR35","first-page":"s127","volume":"126","author":"TRR Lal","year":"2019","unstructured":"Lal TRR, Crosby CG, Hicks K, Tanpaiboon R. Newborn screen for MPS1 (Hurler syndrome)\u2014the Washington,\u00a0DC experience. Mol Genet Metab. 2019;126(2):s127.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1880_CR36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jpeds.2013.01.031","volume":"163","author":"CR Scott","year":"2013","unstructured":"Scott CR, Elliott S, Buroker N, Thomas LI, Keutzer J, Glass M, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr. 2013;163(2):498\u2013503.","journal-title":"J Pediatr"},{"issue":"4","key":"1880_CR37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/ijns6040085","volume":"6","author":"V Gragnaniello","year":"2020","unstructured":"Gragnaniello V, Gueraldi D, Rubert L, Manzoni F, Cazzorla C, Giuliani A, et al. Report of five years of experience in neonatal screening for mucopolysaccharidosis Type I and review of the literature. Int J Neonatal Screen. 2020;6(4):85.","journal-title":"Int J Neonatal Screen"},{"issue":"7","key":"1880_CR38","first-page":"508","volume":"10","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J. Initial report from the Hunter outcome survey. Genet Sci. 2008;10(7):508\u201316.","journal-title":"Genet Sci"},{"issue":"3","key":"1880_CR39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","volume":"121","author":"SA Khan","year":"2017","unstructured":"Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, et al. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121(3):227\u201340.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1880_CR40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","volume":"12","author":"R Pinto","year":"2004","unstructured":"Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004;12(2):87\u201392.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"1880_CR41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1746-1596-6-113","volume":"6","author":"L Chkioua","year":"2011","unstructured":"Chkioua L, Khedhiri S, Ben Turkia H, Chahed H, Ferchichi S, Ben Dridi MF, et al. Hurler disease (mucopolysaccharidosis type IH): clinical features and consanguinity in Tunisian population. Diagn Pathol. 2011;6(1):113.","journal-title":"Diagn Pathol"},{"issue":"3","key":"1880_CR42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004390050641","volume":"101","author":"J Nelson","year":"1997","unstructured":"Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101(3):355\u20138.","journal-title":"Hum Genet"},{"issue":"4","key":"1880_CR43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/0256-4947.65254","volume":"30","author":"H Moammar","year":"2010","unstructured":"Moammar H, Cheriyan G, Mathew R, Al-Sannaa N. Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983\u20132008. Ann Saudi Med. 2010;30(4):271\u20137.","journal-title":"Ann Saudi Med"},{"issue":"1\u20134","key":"1880_CR44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000358404","volume":"77","author":"FM Costa-Motta","year":"2014","unstructured":"Costa-Motta FM, Bender F, Acosta A, Abe-Sandes K, Machado T, Bomfim T, et al. A community-based study of mucopolysaccharidosis type VI in Brazil: the influence of founder effect, endogamy and consanguinity. Hum Hered. 2014;77(1\u20134):189\u201396.","journal-title":"Hum Hered"},{"issue":"4","key":"1880_CR45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ped.12281","volume":"56","author":"A Jurecka","year":"2014","unstructured":"Jurecka A, Zakharova E, Cimbalistiene L, Gusina N, Malinova V, Rozdzynska-Swiatkowska A, et al. Mucopolysaccharidosis type VI in Russia, Kazakhstan, and Central and Eastern Europe. Pediatr Int. 2014;56(4):520\u20135.","journal-title":"Pediatr Int"},{"issue":"2","key":"1880_CR46","first-page":"330","volume":"53","author":"G Bach","year":"1993","unstructured":"Bach G, Moskowitz SM, Tieu PT, Matynia A, Neufeld EF. Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. Am J Hum Genet. 1993;53(2):330\u20138.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"1880_CR47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10038-005-0258-4","volume":"50","author":"Y Chinen","year":"2005","unstructured":"Chinen Y, Tohma T, Izumikawa Y, Uehara H, Ohta T. Sanfilippo type B syndrome: five patients with an R565P homozygous mutation in the alpha-N-acetylglucosaminidase gene from the Okinawa islands in Japan. J Hum Genet. 2005;50(7):357\u20139.","journal-title":"J Hum Genet"},{"issue":"1","key":"1880_CR48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.patbio.2013.10.001","volume":"62","author":"S Khedhiri","year":"2014","unstructured":"Khedhiri S, Chkioua L, Elcioglu N, Laradi S, Miled A. Mutations and polymorphisms in N-acetylgalactosamine-6-sulfate sulfatase gene in Turkish Morquio A patients. Pathol Biol. 2014;62(1):38\u201340.","journal-title":"Pathol Biol"},{"issue":"3","key":"1880_CR49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/109065702761403388","volume":"6","author":"PL Rady","year":"2002","unstructured":"Rady PL, Surendran S, Vu AT, Hawkins JC, Michals-Matalon K, Tyring SK, et al. Founder mutation R245H of Sanfilippo syndrome type A in the Cayman Islands. Genet Test. 2002;6(3):211\u20135.","journal-title":"Genet Test"},{"issue":"5","key":"1880_CR50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ajmg.a.32781","volume":"149A","author":"HY Lin","year":"2009","unstructured":"Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984\u20132004. Am J Med Genet A. 2009;149A(5):960\u20134.","journal-title":"Am J Med Genet A"},{"issue":"11","key":"1880_CR51","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1651-2227.2008.00965.x","volume":"97","author":"G Malm","year":"2008","unstructured":"Malm G, Lund AM, Mansson JE, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr. 2008;97(11):1577\u201381.","journal-title":"Acta Paediatr"},{"issue":"3","key":"1880_CR52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5582\/irdr.2014.01013","volume":"3","author":"SY Cho","year":"2014","unstructured":"Cho SY, Sohn YB, Jin DK. An overview of Korean patients with mucopolysaccharidosis and collaboration through the Asia Pacific MPS Network. Intractable Rare Dis Res. 2014;3(3):79\u201386.","journal-title":"Intractable Rare Dis Res"},{"issue":"8","key":"1880_CR53","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1089\/gtmb.2011.0307","volume":"16","author":"K Krabbi","year":"2012","unstructured":"Krabbi K, Joost K, Zordania R, Talvik I, Rein R, Huijmans JG, et al. The live-birth prevalence of mucopolysaccharidoses in Estonia. Genet Test Mol Biomark. 2012;16(8):846\u20139.","journal-title":"Genet Test Mol Biomark"},{"issue":"1\u20132","key":"1880_CR54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105(1\u20132):151\u20136.","journal-title":"Hum Genet"},{"issue":"1","key":"1880_CR55","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1542\/peds.105.1.e10","volume":"105","author":"DA Applegarth","year":"2000","unstructured":"Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969\u20131996. Pediatrics. 2000;105(1):e10.","journal-title":"Pediatrics"},{"issue":"4","key":"1880_CR56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10545-010-9093-7","volume":"33","author":"H Poupetova","year":"2010","unstructured":"Poupetova H, Ledvinova J, Berna L, Dvorakova L, Kozich V, Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis. 2010;33(4):387\u201396.","journal-title":"J Inherit Metab Dis"},{"key":"1880_CR57","unstructured":"Hahn S. Mucopolysaccharidoses: clinical features and diagnosis. In: Patterson MC, TePas E, editors. UpToDate, Waltham, MA;\u00a02019. Accessed 25 Apr 2021."},{"issue":"1","key":"1880_CR58","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s13023-020-01608-0","volume":"15","author":"P Borges","year":"2020","unstructured":"Borges P, Pasqualim G, Giugliani R, Vairo F, Matte U. Estimated prevalence of mucopolysaccharidoses from population-based exomes and genomes. Orphanet J Rare Dis. 2020;15(1):324.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01880-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T05:15:36Z","timestamp":1625548536000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01880-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,29]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1880"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01880-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,29]]},"assertion":[{"value":"5 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The IRB at Saint Louis University determined that our human subjects research was exempt from a formal IRB submission due to lack of patient identifiers or protected health information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}